Nov 13, 2018
The pancreatic cancer drug of GlaxoSmithKline moves to phase 1 The experimental drug, GSK095 of GlaxoSmithKline is made to work in order with a checkpoint that are inhibiting medicines in the empowerment of the immune system to introduce a more aggressive attack against tumours than with checkpoint inhibitors alone...
Read More...
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper